National Foundation for Cancer Research
Lungevity Foundation shared a recent article by Yi-Long Wu, commenting:
“What’s after osimertinib for pts with EGFR+ NSCLC? Researchers are working on options… just released. primary analysis of the phase 2 INSIGHT 2 study of tepotinib, a highly selective MET inhibitor, combined with osimertinib at EGFR Resisters and EGFR Positive UK.”
Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber Cancer Institute, also added:
“Tepotinib plus osimertinib in EGFR+ and NSCLC with MET amp following progression on first-line osimertinib (INSIGHT 2).
- ORR 50% (56.6% if MET GCN >10; 42.2% if <10)
- On target resistance after combo in 34% pts
Title: Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
Author: Yi-Long Wu , Valentina Guarneri , Pei Jye Voon , Boon Khaw Lim , Jin-Ji Yang , Marie Wislez , Cheng Huang, Chong Kin Liam , Julien Mazieres , Lye Mun Tho , Hidetoshi Hayashi , Nguyen Viet Nhung , Puey Ling Chia , Filippo de Marinis , Jo Raskin , Qinghua Zhou , Giovanna Finocchiaro , Anh Tuan Le , Jialei Wang , Christophe Dooms , Terufumi Kato , Ernest Nadal , How Soon Hin , Egbert F Smit , Martin Wermke , Daniel Tan , Masahiro Morise , Aurora O’Brate , Svenja Adrian , Boris M Pfeiffer , Christopher Stroh , Dilafruz Juraeva , Rainer Strotmann , Kosalaram Goteti , Karin Berghoff, Barbara Ellers-Lenz , Niki Karachaliou , Xiuning Le , Tae Min Kim ; INSIGHT 2 investigators
